Summary Puromycin-resistant (PurR) mutants/variants of a human carcinoma cell line (HeLa), which show greatly reduced cellular uptake of 3H-puromycin and 3H-daunomycin have been isolated after one-and twostep selections in presence of the drug. The cross-resistance pattern of these mutant cell lines towards numerous anticancer drugs and other inhibitors has been examined. Both the first-and the second-step mutants exhibited increased resistance to a number of antimitotic drugs (viz. vinblastine, vincristine, colchicine, taxol and maytansine), several protein synthesis inhibitors (viz. chalcomycin, bruceantin, harringtonine, homoharringtonine), a large number of DNA interactive compounds (viz. aclacinomycin A, actinomycin D, adriamycin, m-AMSA, chromomycin A3, coralyne sulphoacetate, daunomycin, ellipticine, mithramycin, mitoxantrone, 5-methoxysterigmatocystin, rubidazone, variamycin, VM26 and VP16-213) and a number of other drugs acting via other mechanisms (viz. Baker's antifol, nitidine chloride and rhodamine 123). Whereas the first-step mutants showed stable resistance to these drugs, the second-step lines partially reverted upon growth in non-selective medium. Further, treatment of these mutant lines with noncytotoxic doses of the calcium channel blocker verapamil reverted or abolished their resistance to the above drugs in a dose-dependent manner. In contrast to the above compounds, the PurR mutants showed no significant cross-resistance to a large number of other drugs which included asaley, AT-125, 5-azacytidine, azaserine, cyclocytidine, cis-platin, cytosine arabinoside, chlorambucil, chlorpromazine, a-difluoromethyl ornithine, 5-fluorouracil, ftorafur, gallium nitrate, hydroxyurea, ICRF-159, ICRF-187, imipramine, methotraxate, 6-methylmercaptopurine riboside, mycophenolic acid, melphalan, mitomycin C, methyl GAG, nafoxidine, reumycin, 6-selenoguanosine, 6-thioguanine, tiazofurin, tamoxifen, thalicarpine, tiapamil and verapamil). These cross-resistance data should prove useful in developing suitable drug combinations to which cellular resistance would not develop readily.
The development of resistance to chemotherapeutic drugs of a tumour cell cell population is one of the major obstacles in successful treatment of cancers. While some tumours may be intrinsically resistant to drugs, a more common cause is perceived to be the selection and expansion of a resistant cell population, during the course of chemotherapy (Shoemaker et al., 1983; Goldie & Coldman, 1984) . To avoid development of drug-resistance, a combination of drugs, acting at different cellular targets and/or by different mechanisms, are commonly employed in chemotherapy (Devita & Schein, 1973; Goldie et al., 1982) . It is hoped that the cells resistant to one drug will be killed by the other and that resistance to the drug combination would not readily develop. However, extensive studies with animals and cell culture model systems during the past 15-20 years have revealed that in one of the most commonly encountered mode of drug resistance, resistance to multiple, structurally and functionally unrelated drugs (e.g., vinblastine, vincristine, adriamycin, daunomy- cin, actinomycin D, colchicine, puromycin, etc.) develops readily and simultaneously (Dano, 1972; Skovsgaard, 1978; Beidler et al., 1983; Ling et al., 1983; Akiyama et al., 1985; Twentyman et al., 1986a; Beck, 1987) . This multidrugresistance (MDR) phenotype underscores the fact that the cross-resistance pattern of cells to various drugs cannot be predicted a priori, based only on the information regarding structures and/or mechanisms of action of drugs. Therefore, in order to use the available anticancer drugs most effectively, it is of much importance to experimentally obtain the information regarding drug cross-resistance patterns, particularly with the cells exhibiting MDR phenotype (Schabel et al., 1983; Hill, 1984; Gupta, 1985; Twentyman et al., 1986b) .
To obtain detailed information in this regard in a human tumour cell line, puromycin resistant (PurR) mutants of here. Further, effect of treatment of the mutant cells with verapamil, a calcium channel blocker which has earlier been reported to sensitize the drug resistant cells (Tsuruo et al., 1981; Beck, 1984; Rogan et al., 1984; Twentyman et al., 1986b) , on the cellular resistance towards drugs has been examined.
Materials and methods
Cell lines and culture conditions HeLa (clone S3) and its drug-resistant variants were grown routinely in monolayers in alpha MEM supplemented with 5% foetal bovine serum at 37°C in 95% air, 5% CO2 atmosphere (Singh & Gupta, 1985) . Except where stated, the cells were grown in the absence of any selective drugs.
Measurement of the degree of drug resistance The degree of resistance of any cell line towards a given drug was determined by seeding 100 and 250 cells of the parental and the mutant cell lines in duplicate (in 0.5 ml of growth medium) into the wells of 24-well tissue culture dishes containing 0.5 ml of various drug dilutions made twice the final concentrations desired in the growth medium. (Gupta, 1983a, b) . Exponentially growing HeLa cells were treated with 400 g ml -1 of the mutagen ethyl methanesulphonate (EMS) for 20 h. This treatment results in about 50% cell killing (Gupta, 1983b Cellular accumulation of labelled drugs For studying the cellular accumulation of 3H-labelled drugs, 1 x 105 cells were seeded (in duplicate for each time period) into the wells of 24-well tissue culture dishes. After about 2 days, when the dishes were nearly confluent, the medium was carefully aspirated, and 0.25 ml of a solution containing desired concentrations of the labelled drugs (3H-puromycin, 1 x 10 -9 M; 3H-daunomycin, 2 x 10-7 M) in growth medium was added to each well. After 30 min, the labelled medium was removed, and cells were rinsed 3 times with PBS. The cells from each well were dissolved in 0.25 ml of a solution of 0.4% deoxycholic acid in 0.1 N NaOH, and the amount of radioactivity was measured after the addition of 3 to 4 ml of aqueous counting scintillant (Amersham/ Searle Corp., Arlington Heights, IL). At the same time, total numbers of cells in 2 parallel control wells of each cell line were determined by trypsinization and the counting of aliquots in a Coulter electronic counter. The cellular accumulation of 3H-labelled drugs in different cell lines was normalized for a constant cell number.
Results
The plating efficiency of HeLa cells in the presence of puromycin decreases sharply in the concentration range of 0.05-0.15 pugml-1 (Figure 1 ), and it becomes <lx10 at 0.2 pg ml-drug. The selection of resistant clones was attempted in both mutagen (EMS)-treated and untreated cells using 0.25 pgml-1 puromycin. In the control cultures, no resistant colonies were observed from a total of 1.6 x 107 viable cells (mutation frequency < 6.3 x 10-8). However, in the EMS-treated cultures, resistant colonies were obtained at a frequency of -1 per 2 x 106 cells. The dose response curve for puromycin for one of the clones (viz. PurRI27) which was picked and grown in non-selective medium is shown in Figure 1 . Based on its D10 value for puromycin, this mutant clone is 10-fold resistant in comparison to the HeLa cells. A number of other clones which were similarly examined showed lower degrees of resistance to puromycin and were not investigated further. The drug-resistant phenotype of PurR127 is stably retained upon growth in nonselective medium for more than one year.
The PurRI27 mutant was employed to select second-step mutants (in presence of 10 gml-l puromycin) that exhibited a higher degree of resistance to the drug. From EMStreated cultures, the second-step mutants were obtained at a frequency of 1.4 x 10 -6 which was 10-fold higher than that observed in non-mutagenized cells. Three individual secondstep colonies were picked and grown in medium containing 10lpgml-l puromycin. Based on their D1o values for puromycin, these clones were between 80-to 130-fold more resistant in comparison to the parental HeLa cells. The doseresponse curve for PurR17, which has been further investigated is depicted in (Dano, 1973; Cremisi et al., 1974; Inaba & Johnson, 1977; Skovsgaard, 1978) , accumulation of 3H-puromycin and 3H-daunomycin in the parental and mutant cell lines was investigated. From the results of these studies presented in Table I , it is evident that in comparison to the parental HeLa cells, intracellular levels of both drugs in the resistant lines were much lower. Further, the second-step mutant which exhibited higher degree of resistance to puromycin, had lower intracellular drug levels, in comparison to the PurRI27 line. The reduced intracellular levels of both 3H-puromycin as well as 3H-daunomycin in the resistant cells indicated that the genetic lesion in these mutants was similar to that observed in other MDR mutants selected using other anticancer drugs. The PurR variants of other mammalian cell types (viz. mouse fibroblasts, pig kidney cells, Chinese hamster V79 cells) which have earlier been reported (Lieberman & Ove, 1959; Cass, 1972; Morrow et al., 1980 ) also showed reduced cellular accumulation of the drug.
Cross resistance pattern of the mutants towards other drugs Earlier studies with mutants of Chinese hamster and human cells selected for resistance to several anticancer drugs, e.g. actinomycinD, daunomycin, vinblastine, vincristine, colchicine, taxol, VM26, VP16, etc. show that they all exhibit cross resistance towards puromycin (Biedler et al., 1983; Ling et al., 1983; Gupta, 1983b; Hill, 1984; Akiyama et al., 1985; Gupta, 1985; Meyers et al., 1985) . In view of this and the results of uptake studies, cross resistance pattern of the PurR mutants towards a wide variety of anticancer drugs and other inhibitors was examined. As expected, the PurR mutants exhibited increased resistance towards a large number of drugs (Table I) , which included several antimitotic drugs (viz. colchicine, vinblastine, taxol and maytansine), a large number of DNA intercalating and/or interacting compounds (viz. aclacinomycin A, actinomycin D, adriamycin, m-AMSA, chromomycin A3, coralyne sulphoacetate, daunomycin, ellipticine, mithramycin, 5-MSC rubidazone, variamycin, VM26 and VP16-213) and numerous other compounds acting via other mechanisms. For all of these drugs the second-step mutant PurRII7 exhibited higher degree of resistance in comparison to the PurR127 line. However, in contrast to the PurRI27 line whose resistance /cross-resistance was completely stable in non-selective medium (this cell line is routinely grown in non-selective medium), growth of PurRII7 in puromycin-free medium led to either partial or complete reversal of its drug-resistant phenotype (i.e., dropping to a similar level as PurR127 from which it is derived by a second-step selection).
In contrast to the drugs listed in Table II , the PurRI or PurRII cell lines showed no cross-resistance towards a large number of other drugs and inhibitors (Table III) . These drugs included various antimetabolites (AT-125, 5-azacytidine, cyclocytidine, cytosine arabinoside (Ara C), a-DFMO, ftorafur, 5-fluorouracil, hydroxyurea, methotrexate, 6-methylmercaptopurine riboside (6-MeMPR), mycophenolic acid, 6-selenoguanosine, 6-thioguanine), alkylating agents (chlorambucil, melphalan, mitomycinC, etc.) and a large number of other drugs and inhibitors acting via other mechanisms (e.g., cis-platin, chloropromazine, ellipticine, methyl GAG, reumycin, tiazofurin, tamoxifen, thalicarpine, verapamil, etc.) . It is noteworthy that the PurR mutants showed no differences in sensitivity towards verapamil, to which the vincristine-resistant mutants of Chinese hamster cells have been reported to show enhanced sensitivity (Warr et al., 1986 15ugml-1, had no cytotoxic or growth inhibitory effect on any of the above cell lines. Table IV presents the results of our studies on examining the effect of non-cytotoxic concentrations of verapamil on the drug-sensitivity of the parental and resistant cell lines.
Treatment with 10jugml-l verapamil had a very marked effect on the level of resistance of the PurR line towards various drugs but had no effect on the drug sensitivity of the HeLa cell lines. For all of the drugs examined (viz. puromycin, taxol, actinomycin D, vinblastine, daunomycin, mitoxantrone, bisantrene, VP16), nearly complete reversal of drugresistance was noted at lOgml-l verapamil. Further, as shown for puromycin and taxol, the extent of reversal of drug-resistance was directly related to the concentration of verapamil in the growth medium. For both puromycin and taxol at 1 and 3 gml-1 verapamil, only partial reversal of drug-resistance for the PurR mutants was observed.
Discussion
This paper describes the selection and detailed crossresistance pattern of mutants of HeLa cells resistant to the protein synthesis inhibitor puromycin. The PurR mutants described here showed much lower accumulation of 3H-labelled drugs, which correlated with the level of resistance of the mutant cells. Further, these mutants exhibit high levels of cross-resistance to a wide variety of structurally and functionally unrelated compounds. Based on these characteristics, the genetic lesion in these mutants should be similar to that observed in other multidrug-resistant cell lines selected for resistance to other drugs, such as vinblastine, vincristine, adriamycin, daunomycin, actinomycin D, colchicine, taxol, etc. (Dano, 1972; Skovsgaard, 1978; Biedler et al., 1983; Gupta, 1983b; Ling et al., 1983; Akiyama et al., 1985; Gupta, 1985) . The biochemical basis of MDR in Chinese hamster, mouse leukaemia and human leukaemia and KB cells has been extensively studied in recent years. These studies indicate that multiple factors could contribute to the development of MDR phenotype (Riordan & Ling, 1985; Beck, 1987) . These include (i) decreased rate of drug uptake or influx; (ii) enhanced active efflux or transport of the drugs, and (iii) altered/reduced intracellular binding of the drug(s). In addition, the cell lines exhibiting high levels of MDR most frequently show increased expression of a family of cell surface glycoproteins (commonly referred to as P glycoproteins), which results from amplification of the corresponding genes (Ling et al., 1983; Roninson et al., 1984; Beck, 1987) . Although our preliminary studies The main emphasis of the current work, however, was on examining in detail the cross-resistance pattern of a human MDR cell line towards various anticancer drugs. In the past, only limited studies in this regard with the human MDR cell lines have been reported (Beck, 1983; Akiyama et al., 1985; Twentyman et al., 1986a, b) . For many of the drugs employed in the present investigation (viz. Baker's antifol, chalcomycin, coralyne sulphoacetate, harringtonine, homoharringtonine, tamoxifen, reumycin and thalicarpine, etc.), the cross-resistance of the MDR cell line has been examined for the first time. Based on the cross-resistance pattern of the PurR mutants, the drugs which have been examined could be divided into two groups: those to which the MDR mutants exhibit increased resistance (Table II) and the others for which no significant change in resistance is observed (Table  III) In an earlier study the cross resistance pattern of singlestep mutants of Chinese hamster ovary (CHO) cells selected for resistance to either vinblastine or taxol to a large number of these drugs was examined (Gupta, 1985) . A comparison of the results of these two studies indicates that the cross resistance patterns of these independently selected mutants resistant to various drugs (viz. taxol, vinblastine and puromycin) in cells of two different species, are virtually identical.
The pattern observed here is also in accordance with the results of limited cross resistance studies carried out with various other MDR cell lines of different species reported in the literature (Dano, 1972; Skovsgaard, 1981; Beck, 1983; Biedler et al., 1983; Ling et al., 1983; Akiyama et al., 1985; Twentyman et al., 1986) . These results provide strong evidence that the MDR mutants of different species exhibit increased resistance to the same specific group of drugs, listed in Table I , 1977; Shoemaker et al., 1983) . Recently, increased expression of P-glycoprotein or of the corresponding gene, in a number of human tumours which are refractory to chemotherapy, has also been reported (Bell et al., 1985; Gerlach et al., 1986; Fojo et al., 1987 (Inaba et al., 1981; Tsuruo et al., 1981 Tsuruo et al., , 1984 Ganpathi & Grabowski, 1983; Beck, 1984; Akiyama et al., 1988) . Although the mechanism by which these compounds cause reversal of the MDR is unclear at present, the use of one of these agents in combination with the drugs listed in Table I should enhance the chemotherapeutic effectiveness of the latter drugs. Based on the above considerations, more effective chemotherapeutic drug combinations in principle could be obtained by combining the above two strategies, i.e., employing a drug from the first group (Table II) in conjunction with an agent which overcomes MDR and one or more drugs from the second group (Table III) , to which the MDR mutants do not exhibit cross resistance.
